Finnish biomedical startup Nightingale Health has obtained CE marking for its blood biomarker analysis platform. The CE mark enables the clinical use of the analysis service and the analysed measures of creatinine and glucose in the EU region.Nightingale Health's blood biomarker analysis platform is based on NMR (Nuclear Magnetic Resonance) spectroscopy. It captures over 228 metabolic biomarkers from a single blood sample, transforming the possibility to understand molecular mechanisms and
Read More